Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
The stock market has entered a new period of increased uncertainty and volatility following the Trump Administration's desire to reshape America's trade policies. While the market hasn't crashed outright, it has experienced multiple sessions of sharp losses, as well as dramatic rebounds.
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Ms. Kristin C. Peck CEO | XMEX Exchange | US98978V1035 ISIN |
US Country | 14,100 Employees | 21 Apr 2025 Last Dividend | - Last Split | 1 Feb 2013 IPO Date |